Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate

CONTEXT: In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Endocrinol Metab
Главные авторы: Tsai, Joy N., Zhu, Yuli, Foley, Katelyn, Lee, Hang, Burnett-Bowie, Sherri-Ann, Neer, Robert M., Leder, Benjamin Z.
Формат: Artigo
Язык:Inglês
Опубликовано: Endocrine Society 2015
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5393530/
https://ncbi.nlm.nih.gov/pubmed/25933031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-1541
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы